{
  "source": "PA-Med-Nec-Austedo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2138-9\nProgram Prior Authorization/Medical Necessity\nMedication Austedo® (deutetrabenazine), Austedo® XR (deutetrabenazine)\nP&T Approval Date 11/2017, 11/2018, 11/2019, 11/2020, 2/2022, 2/2023, 4/2023, 4/2024,\n4/2025\nEffective Date 7/1/2025\n1. Background\nAustedo and Austedo XR are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated\nin adults for the treatment of chorea associated with Huntington’s disease and for the treatment\nof tardive dyskinesia.\n2. Coverage Criteriaa:\nA. Tardive Dyskinesia\n1. Initial Authorization\na. Austedo or Austedo XR will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe tardive dyskinesia\n-AND-\n(2) One of the following:\n(a) Patient has persistent symptoms of tardive dyskinesia despite a trial of dose\nreduction, tapering, or discontinuation of the offending medication\n-OR-\n(b) Patient is not a candidate for a trial of dose reduction, tapering, or\ndiscontinuation of the offending medication\n-AND-\n(3) Prescribed by or in consultation with one of the following:\n(a) Neurologist\n(b) Psychiatrist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to therapy\n© 2025 UnitedHealthcare Services Inc.\n1\nAuthorization will be issued for 12 months.\nB. Chorea associated with Huntington’s disease\n1. Initial Authorization\na. Austedo or Austedo XR will be approved based on both of the following criteria:\n(1) Diagnosis of chorea associated with Huntington's disease\n-AND-\n(2) Prescribed by or in consultation with one of the following:\n(a) Neurologist\n(b) Psychiatrist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other poli",
    "\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place\n4. References:\n1. Austedo – Austedo XR [package insert]. Parsippany, NJ: Teva Pharmaceuticals Inc.;\nFebruary 2025.\nProgram Prior Authorization/Medical Necessity - Austedo (deutetrabenazine)\nChange Control\n11/2017 New program\n11/2018 Annual review. No changes to clinical coverage criteria.\n11/2019 Annual review. No changes to clinical coverage criteria. Updated\nreference.\n© 2025 UnitedHealthcare Services Inc.\n2\n11/2020 Annual review. Updated references.\n2/2022 Annual review with no change to clinical criteria.\n2/2023 Annual review. Updated background per package insert and updated\nreferences.\n4/2023 Added coverage criteria for Austedo XR formulation per prescribing\ninformation. Updated background and references.\n4/2024 Annual review with no change to clinical criteria. Reference updated.\n4/2025 Annual review with no change to clinical criteria. References updated.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}